Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 17890451)

1.

High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.

Herling M, Patel KA, Teitell MA, Konopleva M, Ravandi F, Kobayashi R, Jones D.

Blood. 2008 Jan 1;111(1):328-37. Epub 2007 Sep 21.

2.

High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.

Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ, Jones D.

Blood. 2009 Nov 19;114(21):4675-86. doi: 10.1182/blood-2009-03-208256. Epub 2009 Sep 21.

3.

T cell leukemia-1 modulates TCR signal strength and IFN-gamma levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation.

Hoyer KK, Herling M, Bagrintseva K, Dawson DW, French SW, Renard M, Weinger JG, Jones D, Teitell MA.

J Immunol. 2005 Jul 15;175(2):864-73.

4.

[Transgenic mice expressing MTCP1: an animal model for T-cell prolymphocytic leukemia].

Chiali-Gritti C.

Ann Pharm Fr. 2000 Jan;58(1):54-61. French.

PMID:
10669814
5.

Proto-oncogene TCL1: more than just a coactivator for Akt.

Noguchi M, Ropars V, Roumestand C, Suizu F.

FASEB J. 2007 Aug;21(10):2273-84. Epub 2007 Mar 14. Review.

7.

Differential regulation of Akt kinase isoforms by the members of the TCL1 oncogene family.

Laine J, Künstle G, Obata T, Noguchi M.

J Biol Chem. 2002 Feb 1;277(5):3743-51. Epub 2001 Nov 13.

8.

TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin.

Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D.

Blood. 2003 Jun 15;101(12):5007-9. Epub 2003 Feb 6.

9.

The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCtheta and ERK pathways.

Despouy G, Joiner M, Le Toriellec E, Weil R, Stern MH.

Blood. 2007 Dec 15;110(13):4406-16. Epub 2007 Sep 10.

10.

IL-2-induced growth of CD8+ T cell prolymphocytic leukemia cells mediated by NF-kappaB induction and IL-2 receptor alpha expression.

Arima N, Matsushita K, Suruga Y, Ohtsubo H, Fujiwara H, Hidaka S, Arimura K, Kukita T, Yamaguchi K, Fukumori J, Tanaka H.

Leuk Res. 1998 Mar;22(3):265-73.

PMID:
9619918
11.

T cell receptor-stimulated generation of hydrogen peroxide inhibits MEK-ERK activation and lck serine phosphorylation.

Kwon J, Devadas S, Williams MS.

Free Radic Biol Med. 2003 Aug 15;35(4):406-17.

PMID:
12899942
12.

Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1.

Künstle G, Laine J, Pierron G, Kagami Si S, Nakajima H, Hoh F, Roumestand C, Stern MH, Noguchi M.

Mol Cell Biol. 2002 Mar;22(5):1513-25.

13.

Small cell variant of T-cell prolymphocytic leukemia with a gammadelta immunophenotype.

Toyota S, Nakamura N, Dan K.

Int J Hematol. 2005 Jan;81(1):66-8.

PMID:
15717692
14.

Molecular basis of mature T-cell leukemia.

Pekarsky Y, Hallas C, Croce CM.

JAMA. 2001 Nov 14;286(18):2308-14. Review.

PMID:
11710897
15.

The protooncogene TCL1 is an Akt kinase coactivator.

Laine J, Künstle G, Obata T, Sha M, Noguchi M.

Mol Cell. 2000 Aug;6(2):395-407.

17.

Identification of nerve growth factor-responsive element of the TCL1 promoter as a novel negative regulatory element.

Hiromura M, Suizu F, Narita M, Kinowaki K, Noguchi M.

J Biol Chem. 2006 Sep 22;281(38):27753-64. Epub 2006 Jul 11.

18.
19.
20.

T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present.

Wang Q, Stanley J, Kudoh S, Myles J, Kolenko V, Yi T, Tubbs R, Bukowski R, Finke J.

J Immunol. 1995 Aug 1;155(3):1382-92.

PMID:
7636203
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk